中国当代儿科杂志2026，Vol.28Issue(3)：277-284,8.DOI:10.7499/j.issn.1008-8830.2508180
多配体蛋白聚糖-1对早产儿坏死性小肠结肠炎的诊断价值:一项多中心前瞻性研究
Multicenter prospective study on the diagnostic value of syndecan-1 for necrotizing enterocolitis in preterm infants
摘要
Abstract
Objective To investigate the clinical diagnostic value of the endothelial glycocalyx injury biomarker syndecan-1(SDC-1)for necrotizing enterocolitis(NEC)in preterm infants.Methods A multicenter,prospective study was conducted from February to July 2025 at the First Affiliated Hospital of Army Medical University,Sichuan Maternal and Child Health Hospital,and Liaocheng People's Hospital.Preterm infants with Bell stage Ⅱ-Ⅲ NEC were enrolled as the NEC group(n=38),and contemporaneous non-NEC preterm infants were selected in a 1∶1 ratio as the non-NEC group(n=38).Perinatal data and measurements of complete blood counts,SDC-1,and high-sensitivity C-reactive protein(hs-CRP)were collected.Multivariable logistic regression was used to evaluate risk factors for NEC.Receiver operating characteristic(ROC)curves were used to assess diagnostic performance of SDC-1.Results Neutrophil count,SDC-1,and hs-CRP levels were significantly higher in the NEC group than in the non-NEC group(P<0.05),while platelet count was significantly lower(P<0.05).Elevated SDC-1(OR=1.081,95%CI:1.028-1.137;P<0.05)and hs-CRP(OR=1.267,95%CI:1.051-1.527;P<0.05)were independent risk factors for NEC.ROC analysis showed that SDC-1(cutoff 125 ng/mL)and hs-CRP(cutoff 6.56 mg/L)yielded areas under the curve(AUCs)of 0.882 and 0.863,respectively.Their combination achieved an AUC of 0.938 with a sensitivity of 76.3%and a specificity of 97.4%.Conclusions SDC-1 is a potential biochemical biomarker for diagnosing NEC in preterm infants,but its clinical utility requires further validation in larger-sample studies.关键词
坏死性小肠结肠炎/多配体蛋白聚糖-1/超敏C反应蛋白/早产儿Key words
Necrotizing enterocolitis/Syndecan-1/High-sensitivity C-reactive protein/Preterm infant引用本文复制引用
尹显源,赵智慧,王钰,蔡娜,陈盛..多配体蛋白聚糖-1对早产儿坏死性小肠结肠炎的诊断价值:一项多中心前瞻性研究[J].中国当代儿科杂志,2026,28(3):277-284,8.基金项目
国家自然科学基金项目(82301956、82170565) （82301956、82170565）
重庆市自然科学基金重点项目(2024NSCQ-KJFZZDX0018) （2024NSCQ-KJFZZDX0018）
重庆市科卫联合医学科研项目(2025MSXM037). （2025MSXM037）
